Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495123 | 1.00 | NR1H2 (0.54) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL8448438 | 0.94 | NR1H2 (0.58) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL6099695 | 0.94 | NR1H2 (0.58) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL8229118 | 0.92 | NR1H2 (0.54) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL5369120 | 0.92 | NR1H2 (0.54) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL6099031 | 0.92 | NR1H2 (0.54) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL13705076 | 0.91 | NR1H2 (0.53) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL5378968 | 0.89 | LMNA (0.53) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL3506688 | 0.88 | NR1H2 (0.51) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL3506686 | 0.88 | NR1H2 (0.51) | NR1H2NR1H3CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210635-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-1999117-A2 | RENIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007117961-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210635-A1 | RENIN INHIBITORS | REN, ACE, AGT | NR1H2 1643/4885NR1H3 1391/4885CA1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.